Byung Kwan Park

DWI is a feasible technique that can be used for the differentiation of malignant and benign tissues in the PZ and TZ. Additionally, T2WI with DWI is superior to T2WI alone for the prediction of prostate cancer location.

Delayed enhanced CT can characterize additional hyperattenuating adrenal masses that cannot be characterized with chemical shift MR.

In patients with PSA level and no previous biopsy, 3-T MRI that is performed before transrectal ultrasound-guided biopsy may contribute to the detection of prostate cancer.

The DWI of the prostate at 3T MRI using a phased-array coil was useful for the differentiation of malignant and benign tissues in the TZ and PZ.

Renal AML can be classified according to amount of fat as fat rich, fat poor, or fat invisible. To detect fat, one needs to thoroughly evaluate the entire AML by controlling the size and shape of the ROI. Fat-invisible AML should be biopsied, and fat-poor AML requires further investigation to determine whether biopsy is necessary to differentiate it from renal cell carcinoma. If differentiation between AML and renal cell carcinoma is not clear with CT and MRI, percutaneous biopsy may be performe

The 3.0-T phased-array MRI is equivalent to the 1.5-T endorectal MRI in evaluating local staging accuracy for prostate cancer without significant loss of imaging quality.

DWI in addition to T2WI at 3 T has the potential to provide important information on lesion localization in patients that had both previous negative TRUS biopsy and persistently elevated prostate specific antigen levels before a repeated biopsy.

Magnetic resonance imaging is more sensitive than PET/CT for detecting local pelvic recurrence and peritoneal lesions of recurrent ovarian tumors.

: A higher K value at baseline DCE-MRI suggested a poor ablation efficacy of MR-HIFU therapy for symptomatic uterine fibroids.

For treating size- and location-matched RCCs, RFA is superior to OPN with respect to the preservation of renal function. Furthermore, RFA can achieve excellent mid-term outcomes that are equivalent to those of OPN.

No AccessJournal of UrologyLetter to the Editor/Errata1 May 2009Re: Renal Mass Biopsy—A Renaissance?B. R. Lane, M. K. Samplaski, B. R. Herts, M. Zhou, A. C. Novick and S. C. Campbell J Urol 2008; 179: 20–27 Byung Kwan Park Byung Kwan ParkByung Kwan Park More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2009.01.061AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Re: Renal Mass Biops